A. Markham et Jc. Adkins, Inhaled salmeterol/fluticasone propionate combination - A pharmacoeconomicreview of its use in the management of asthma, PHARMACOECO, 18(6), 2000, pp. 591-608
Cost estimates from developed countries indicate that asthma accounts for u
p to 2% of the economic cost of all diseases. A large proportion of asthma-
related costs are attributable to poor asthma control. Treatment strategies
which improve clinical outcomes in patients with asthma, therefore, have t
he potential for significant economic benefits, and it is important to eval
uate new asthma therapies for cost effectiveness.
Several studies have established that salmeterol and fluticasone propionate
combined in a single dry powder inhalation device are at least as effectiv
e as a combination of the 2 drugs administered via separate dry powder inha
lers and more effective than monotherapy with fluticasone propionate or bud
esonide. Importantly, pharmacoeconomic analysis of several of these studies
show that the salmeterol/fluticasone propionate combination is cost effect
ive relative to monotherapy with fluticasone propionate or budesonide. Alth
ough the total cost of asthma management tended to be slightly higher with
salmeterol/fluticasone propionate than with inhaled corticosteroid monother
apy, in most cases mean cost-effectiveness ratios were lower (i.e. more fav
ourable) for salmeterol/fluticasone propionate than either fluticasone prop
ionate or budesonide. Cost effectiveness was assessed according to 3 end-po
ints: successfully treated weeks, symptom free days and episode-free days.
Mean cost-effectiveness ratios consistently favoured salmeterol/fluticasone
propionate over the comparator drug for the end-point successfully treated
weeks, and in most cases the other 2 end-points also favoured the combinat
ion product over the comparator. In a further study, salmeterol/fluticasone
was also less costly than therapy with formoterol and budesonide administe
red via 2 separate inhalers.
Studies of health-related quality of life (HR-QOL) using the Asthma Quality
of Life Questionnaire indicate that salmeterol/fluticasone propionate prod
uces clinically meaningful improvements in overall HR-QOL relative to salme
terol monotherapy or placebo. Improvements in overall HR-QOL were statistic
ally significantly greater for salmeterol/fluticasone propionate than with
fluticasone propionate or budesonide alone, although the differences betwee
n treatments did not exceed the threshold for clinical significance.
In conclusion, short term cost-effectiveness data show that salmeterol/ flu
ticasone propionate is more cost effective than the inhaled corticosteroids
budesonide and fluticasone propionate alone. The combination product also
appears to improve HR-QOL relative to placebo or salmeterol alone.